Logo image of COCP

COCRYSTAL PHARMA INC (COCP) Stock Fundamental Analysis

NASDAQ:COCP - US19188J4094 - Common Stock

1.46 USD
-0.04 (-2.67%)
Last: 9/3/2025, 3:13:57 PM
Fundamental Rating

2

Taking everything into account, COCP scores 2 out of 10 in our fundamental rating. COCP was compared to 195 industry peers in the Pharmaceuticals industry. COCP has a great financial health rating, but its profitability evaluates not so good. COCP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year COCP has reported negative net income.
In the past year COCP has reported a negative cash flow from operations.
COCP had negative earnings in each of the past 5 years.
In the past 5 years COCP always reported negative operating cash flow.
COCP Yearly Net Income VS EBIT VS OCF VS FCFCOCP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

COCP has a worse Return On Assets (-147.70%) than 84.10% of its industry peers.
COCP has a worse Return On Equity (-235.55%) than 72.82% of its industry peers.
Industry RankSector Rank
ROA -147.7%
ROE -235.55%
ROIC N/A
ROA(3y)-95.52%
ROA(5y)-64.44%
ROE(3y)-118.44%
ROE(5y)-78.4%
ROIC(3y)N/A
ROIC(5y)N/A
COCP Yearly ROA, ROE, ROICCOCP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for COCP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COCP Yearly Profit, Operating, Gross MarginsCOCP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for COCP remains at a similar level compared to 1 year ago.
COCP has more shares outstanding than it did 5 years ago.
There is no outstanding debt for COCP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
COCP Yearly Shares OutstandingCOCP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
COCP Yearly Total Debt VS Total AssetsCOCP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -56.93, we must say that COCP is in the distress zone and has some risk of bankruptcy.
COCP has a Altman-Z score of -56.93. This is amonst the worse of the industry: COCP underperforms 91.28% of its industry peers.
COCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -56.93
ROIC/WACCN/A
WACCN/A
COCP Yearly LT Debt VS Equity VS FCFCOCP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

COCP has a Current Ratio of 3.69. This indicates that COCP is financially healthy and has no problem in meeting its short term obligations.
COCP has a better Current ratio (3.69) than 61.54% of its industry peers.
A Quick Ratio of 3.69 indicates that COCP has no problem at all paying its short term obligations.
COCP's Quick ratio of 3.69 is fine compared to the rest of the industry. COCP outperforms 63.59% of its industry peers.
Industry RankSector Rank
Current Ratio 3.69
Quick Ratio 3.69
COCP Yearly Current Assets VS Current LiabilitesCOCP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.94% over the past year.
EPS 1Y (TTM)29.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

COCP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.72% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.47%
EPS Next 2Y18.51%
EPS Next 3Y10.72%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
COCP Yearly Revenue VS EstimatesCOCP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2019 2020 2M 4M 6M
COCP Yearly EPS VS EstimatesCOCP Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for COCP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COCP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COCP Price Earnings VS Forward Price EarningsCOCP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COCP Per share dataCOCP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.51%
EPS Next 3Y10.72%

More info and screens

0

5. Dividend

5.1 Amount

COCP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COCRYSTAL PHARMA INC

NASDAQ:COCP (9/3/2025, 3:13:57 PM)

1.46

-0.04 (-2.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners7.36%
Inst Owner Change-8.31%
Ins Owners16.93%
Ins Owner Change0%
Market Cap14.98M
Analysts82.5
Price Target7.14 (389.04%)
Short Float %0.42%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.99%
Min EPS beat(2)34.64%
Max EPS beat(2)55.35%
EPS beat(4)4
Avg EPS beat(4)36.63%
Min EPS beat(4)15.72%
Max EPS beat(4)55.35%
EPS beat(8)7
Avg EPS beat(8)27.32%
EPS beat(12)10
Avg EPS beat(12)19.93%
EPS beat(16)12
Avg EPS beat(16)-14.67%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.5%
PT rev (3m)-16%
EPS NQ rev (1m)26.75%
EPS NQ rev (3m)56.25%
EPS NY rev (1m)21%
EPS NY rev (3m)59.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.81
P/tB 2.81
EV/EBITDA N/A
EPS(TTM)-1.24
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-1.3
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -147.7%
ROE -235.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.52%
ROA(5y)-64.44%
ROE(3y)-118.44%
ROE(5y)-78.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.96%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.69
Quick Ratio 3.69
Altman-Z -56.93
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)35.21%
Cap/Depr(5y)56.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.26%
EPS Next Y50.47%
EPS Next 2Y18.51%
EPS Next 3Y10.72%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y40.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.46%
OCF growth 3YN/A
OCF growth 5YN/A